SCHEMBL19077945

SCHEMBL19077945

O=C(O)CCc1ccc(NC(=O)c2ccccc2O)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 6/20 0.68
LMNA P02545 4/20 0.66
KDM4E B2RXH2 4/20 0.66
MEN1 O00255 3/20 0.66
KMT2A Q03164 3/20 0.66
TP53 P04637 3/20 0.66
HTT P42858 3/20 0.66
HSD17B10 Q99714 2/20 0.66
HPGD P15428 1/20 0.66
POLB P06746 1/20 0.63
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59
PNLIP P16233 1/20 0.58
MAPT P10636 2/20 0.55
FFAR1 O14842 2/20 0.54
FFAR4 Q5NUL3 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6381563 0.92 ALOX15 (0.70) ALOX15LMNAKDM4EMEN1KMT2A
SCHEMBL5656623 0.90 ALOX15 (0.72) ALOX15LMNAKDM4EMEN1KMT2A
SCHEMBL13593264 0.89 ALOX15 (0.70) ALOX15LMNAKDM4EMEN1KMT2A
SCHEMBL19077954 0.87 ALOX15 (0.67) ALOX15LMNAKDM4EMEN1KMT2A
SCHEMBL10102771 0.85 FFAR1 (0.71) ALOX15LMNAKDM4EMEN1KMT2A
SCHEMBL5718041 0.85 ALOX15 (0.72) ALOX15LMNAKDM4EMEN1KMT2A
SCHEMBL27541341 0.84 PTGS1 (0.56) ALOX15LMNAKDM4ESMN1; SMN2FFAR1
SCHEMBL13618526 0.84 FFAR1 (0.74) LMNAKDM4EMEN1KMT2AHPGD
SCHEMBL13593315 0.83 PLG (0.70) ALOX15MEN1KMT2APOLBNPC1
SCHEMBL14289116 0.83 CYP2C9 (0.68) LMNAMEN1KMT2AFFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US disclosed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS SI, SLC20A1, SLC20A2 ALOX15 423/4885LMNA 4376/4885KDM4E 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.